Switching statins in Norway after new reimbursement policy - A nationwide prescription study

British Journal of Clinical Pharmacology

Volumn 64, Issue 4, 2007, Pages 476-481

  Sakshaug, Solveig ^a   Furu, Kari ^a   Karlstad, Øystein ^a   Rønning, Marit ^a   Skurtveit, Svetlana ^a,b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Adherence to regulations; Drug costs; Norway; Pharmacoepidemiology; Prescription database; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG SUBSTITUTION; DRUG USE; FEMALE; HEALTH CARE POLICY; HUMAN; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NORWAY; OUTCOME ASSESSMENT; PHYSICIAN; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT;

DRUG COSTS; DRUG UTILIZATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NORWAY; PYRROLES; REIMBURSEMENT MECHANISMS; SIMVASTATIN;

EID: 34548621990     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02907.x     Document Type: Article

References (13)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 9.
2. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005 60 : 543 51.
3. Hågå A, Sverre JM. Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econom 2002 3 : 215 20.
4. Evaluering av Trinnprismodellen (In English : Assessment of the Graded Pricing System). Norwegian Medicines Agency 2006. Available at URL: http://www.legemiddelverket.no/upload/25534/ Evaluering%20av%20Trinnprissystemet%20-%20versjon%202.pdf (last accessed: April 2007).
5. Refusjon: Statiner - nye vilkår for refusjon (In English : Statins - New Reimbursement Regulations). Norwegian Medicines Agency 2005. Available at URL: http://www.legemiddelverket.no/templates/InterPage_21566.aspx (last accessed: April 2007).
6. Rønning M, ed. Legemiddelforbruket i Norge 2001-2005 (In English : Drug Consumption in Norway 2001-2005). Oslo : Norwegian Institute of Public Health 2006.
7. Furu K, Strøm H, Rønning M, Skurtveit S, Engeland A, Tverdal A. The Norwegian Prescription Database (NorPD) - a new register for pharmacoepidemiologic research covering a whole nation. Pharmacoepidemiol Drug Safety 2005 14 : S49.
8. ATC Classification Index with DDDs 2006. Oslo : WHO Collaborating Centre for Drug Statistics Methodology 2005.
9. Guidelines for ATC Classification and DDD Assignment 2006, 9th edn. Oslo : WHO Collaborating Centre for Drug Statistics Methodology 2005.
10. Moon JC, Bogle RG. Switching statins. BMJ 2006 332 : 1344 5.
11. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005 294 : 2437 45.
12. Amarenco P, Bogousslavsky J, Callahan A Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 355 : 549 59.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.